Gene Therapy for Cancer

Kelly K. Hunt, Stephan A. Vorburger, Stephen G. Swisher (Herausgeber)

Buch | Hardcover

469 Seiten

2007
Humana Press Inc. (Verlag)
978-1-58829-472-2 (ISBN)

Artikel merken

The possibility of treating cancer, a disease defined by genetic defects, by introducing genes targeting these very alterations has led to an immense interest in gene therapy for cancer. Although incremental successes have been realized, enthusiasm for gene therapy has declined due to an increasing number of obstacles. These obstacles include vector systems that do not reach systemic metastases, therapeutic genes with redundant mec- nisms allowing for cellular resistance, and toxicities in clinical trials leading to premature closure of these studies. Different tactics to overcome or circumvent these obstacles have catalyzed the development of a wide range of gene therapy approaches. Thus far, almost two-thirds of gene therapy trials have focused on cancer. This reflects the concept that gene therapy approaches for the treatment of cancer do not necessarily require long-term expression of the gene as is necessary for the treatment of primary genetic defects like hemophilia or juvenile diabetes. Unlike the treatment of genetic defects, where expr- sion of the corrected gene needs to be strong, permanent and, sometimes regulated, tactics to treat tumors can be based on temporary and locally limited effects. In addition, cancer cells have different properties than normal cells and this allows for targeting gene therapy to specific cells, a major advantage over current antitumor therapies, which are also toxic to normal cells and tissues.

Vectors.- Adenovector-Mediated Cancer Gene Therapy.- Efficacy, Toxicity, and Immunogenicity of Adenoviral Vectors.- Lentiviral and Retroviral Vector Systems.- Vaccinia and Pox-Virus.- Herpes Simplex Virus as a Therapy for Cancer.- Alphavirus Vectors for Gene Therapy Applications.- Vesicular Stomatitis Virus and RNA Viruses as Gene Therapy Vectors.- Parvovirus Vectors.- Nonviral Vector Systems.- Gene Therapy Approaches.- Oncogenes, Tumor Suppressor Genes and Apoptosis-Inducing Genes Utilized in Cancer Gene Therapy.- Gene Silencing Therapy Against Cancer.- Tumor Targeting-Retargeted Adenovirus.- Oncolytic Herpes Simplex for Gene Therapy in Preclinical and Clinical Trials.- Cytokine Gene Therapy for Genitourinary Cancer.- Combination of Gene Therapy with Radiation.- Gene Transfer for Chemoprotection and Enrichment of Hematopoietic Stem Cells.- Nonviral Genetic Vaccines for Cancer.- Gene Therapy Targeted at Angiogenesis and Lymphangiogenesis for Cancer Treatment.- Tumor-Specific Replicating Adenoviruses.- Clinical Applications.- Problems, Side Effects, and Disappointments in Clinical Cancer Gene Therapy.- Trials and Tribulations in Developing Clinical Trials of Gene Therapy.- Phase I Clinical Experience with Intravenous Administration of PV701, an Oncolytic Virus.- MDA-7/IL-24 as a Multi-Modality Therapy for Cancer.- Development of Therapeutic Genes for Breast Cancer Treatment.- Steps in a Translational Cancer Gene Therapy Trial.

From the reviews:"The book is divided into 3 sections. … this book is informative and provides a comprehensive review of the advances and limitations of cancer gene therapy. … Overall, the book provides enjoyable and instructive reading material. I highly recommend this book to scientists as well as clinicians as a reference source for cancer gene therapy. Readers would benefit from this excellent reading material, whether they are relatively new to this subspecialty or are actively working within the field of cancer gene therapy." (Prem Seth, JAMA, Vol. 299 (11), 2008)"Gene Therapy for Cancer … covers the current technologies of cancer gene therapy as well as the difficult task of applying these in clinical trials. … The book also benefits through its helpful tables, drawings and illustrations. … Gene Therapy for Cancer provides a good overview of currently available techniques for cancer gene therapy and their limitations and potential for clinical applications. The book is a useful addition to the library of both researchers and clinicians working in the field." (S. Schepelmann and C. J. Springer, British Journal of Cancer, Vol. 98 (3), 2008)“This new volume in Humana’s series is written for oncologists, hematologists, cancer researchers, geneticists.” (Tumori, Vol. 93, 2007)

Reihe/Serie	Cancer Drug Discovery and Development
Zusatzinfo	16 Illustrations, color; 69 Illustrations, black and white; XII, 469 p. 85 illus., 16 illus. in color.
Verlagsort	Totowa, NJ
Sprache	englisch
Maße	178 x 254 mm
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Biomedizin
	Medizinische Fachgebiete ► Innere Medizin ► Hämatologie
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
ISBN-10	1-58829-472-2 / 1588294722
ISBN-13	978-1-58829-472-2 / 9781588294722
Zustand	Neuware